B of A Securities analyst Jason Gerberry maintained Pfizer with a Neutral rating and lowered the price target to $26 from $27. The revision reflects a tempered outlook on the stock's near-term performance potential.

Rating and Price Target Changes

The decision to maintain a Neutral stance suggests that the stock is expected to perform in line with the broader market. The reduced price target of $26 indicates a downward adjustment in the valuation expectations compared to the previous target of $27.

Pfizer Limited has recommended a final dividend of ₹75 per equity share of ₹10 each for the financial year ended March 31, 2026. The company reported a 10.4% increase in revenue from operations to ₹2,520 crore, while profit after tax stood at ₹722.43 crore. The 75th Annual General Meeting is scheduled for July 28, 2026, through video conferencing.

The Board of Directors, at its meeting held on May 12, 2026, approved the dividend recommendation. The record date for determining shareholder eligibility is July 17, 2026. If approved at the AGM, the dividend will be paid on or after August 4, 2026.

Financial Highlights

The remote e-voting period will commence on July 24, 2026, and end on July 27, 2026. The cut-off date for determining eligibility for voting is July 21, 2026. The company has appointed KFin Technologies Limited to facilitate the e-voting process.

AGM Agenda

The AGM will transact ordinary business, including the adoption of audited financial statements and the declaration of the final dividend. Special business includes the ratification of remuneration payable to M/s. Kishore Bhatia & Associates, Cost Accountants, for the financial year ending March 31, 2027. The remuneration is fixed at ₹11,00,000 plus applicable taxes and out-of-pocket expenses. The Board has also proposed the re-appointment of Mr. P. Rengan, Director liable to retire by rotation.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE182A01018/a70a18ac531143eb.pdf